Clinical Trial Update: Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating immunogenicity, safety and antibody persistence of a Wuhan-produced COVID-19 booster in patients with hypertension and/or diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• COVID-19 booster vaccine produced in Wuhan

Snippet

Sponsor: China National Biotec Group Company Limited | Conditions: COVID-19 Pneumonia | Phase 4 | Status: UNKNOWN